Hong Kong Stock News

China Jinmao Holdings Group (SEHK:817) has released unaudited contracted sales data for July 2026, giving investors a fresh look at monthly performance and year to date progress across its major development projects. See our latest analysis for China Jinmao Holdings Group. At the latest share price of HK$1.465, China Jinmao Holdings Group has a year to date share price return of 19.11%, while the 1 year total shareholder return has declined 4.92%. This suggests that shorter term momentum has...

Tingyi (Cayman Islands) Holding (SEHK:322) reported higher sales and net income for the half year to June 30, 2026. This points to improved operating performance and gives investors fresh earnings data to assess. See our latest analysis for Tingyi (Cayman Islands) Holding. The latest results from Tingyi (Cayman Islands) Holding come as momentum in the stock has been building, with an 18.1% 1 month share price return and a 35.9% 1 year total shareholder return, suggesting investors are...

Amidst a backdrop of easing inflation concerns and mixed performances across major indices, global markets continue to navigate a complex landscape. For investors seeking unique opportunities, penny stocks—often representing smaller or newer companies—remain an intriguing area of exploration. Despite being considered a throwback term, these stocks can offer growth potential at lower price points when paired with solid financials and strong fundamentals.

Everest Medicines Limited has released its interim results for the half year ended June 30, 2026, reporting CNY 1,147.84 million in sales versus CNY 446.12 million a year earlier and a sharply reduced net loss of CNY 5.94 million compared with CNY 249.79 million. This swing toward near break-even, with basic and diluted loss per share narrowing from CNY 0.77 to CNY 0.02, suggests operating progress that could meaningfully influence how investors view the company’s path to...

CSPC Pharmaceutical Group recently reported three developments: U.S. FDA approval to begin clinical trials for its mpox mRNA vaccine, a US$10,000,000 milestone payment from AstraZeneca tied to their small-molecule collaboration, and a joint venture with AstraZeneca to build a biologics manufacturing facility in Shijiazhuang, China. Together, these moves expand CSPC’s innovative vaccine and drug pipeline while pushing its manufacturing and quality systems further onto the global stage. We’ll...

Unitree Robotics’ huge Shanghai IPO debut has thrown a spotlight on Chinese robotics and automation stocks, as investors look for ways to tap into this wave of excitement and policy support. That surge in attention can quickly reshape how related companies are viewed and valued, which creates both opportunity and risk. This article walks through 3 stocks exposed to the same news, to help you decide which deserve a closer look. The 3 stocks below are just a small sample of what this Chinese...

Half year earnings put Uni-President China Holdings in focus Uni-President China Holdings (SEHK:220) has come into focus after reporting half year earnings to June 30, 2026, with sales of CNY 17,320.97 million and net income of CNY 1,402.35 million. See our latest analysis for Uni-President China Holdings. At a share price of HK$7.905, Uni-President China Holdings has seen a 3.88% 1 month share price return and a 66.55% 3 year total shareholder return, suggesting long term momentum despite a...

We feel now is a pretty good time to analyse Minieye Technology Co., Ltd's ( HKG:2431 ) business as it appears the...

Chongqing Machinery & Electric Co., Ltd. ( HKG:2722 ), is not the largest company out there, but it received a lot of...

The recent price decline of 12% in Huicheng International Holdings Limited's ( HKG:1146 ) stock may have disappointed...

Insiders who bought CN¥5.40m worth of Regal Partners Holdings Limited's ( HKG:1575 ) stock at an average buy price of...

While it’s been a great week for Crosstec Group Holdings Limited ( HKG:3893 ) shareholders after stock gained 25%, they...

It's been a pretty great week for Genscript Biotech Corporation ( HKG:1548 ) shareholders, with its shares surging 15...

As the Asian markets navigate a landscape marked by easing inflationary pressures and shifting economic policies, small-cap stocks have emerged as a focal point for investors seeking growth opportunities. In this dynamic environment, identifying undervalued small-cap companies with notable insider activity can provide insights into potential investment prospects.

Amidst a backdrop of mixed economic signals and geopolitical uncertainties, Asian markets have shown resilience with some indices experiencing notable gains. In this context, identifying undervalued stocks becomes crucial as investors seek opportunities to capitalize on potential discounts in the market.

CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after its allogeneic CAR T-cell candidate CT0596 received IND clearance from China’s National Medical Products Administration for relapsed or refractory multiple myeloma. See our latest analysis for CARsgen Therapeutics Holdings. The CT0596 IND clearance arrives as CARsgen Therapeutics Holdings trades at HK$14.7, with a 1 day share price return of 2.15% and a 90 day share price return down 16.62%. The 1 year total shareholder...

The market has been lukewarm on Billion Industrial Holdings, with the stock flat over the past week and down about 14% over the past month. Yet the latest half year numbers land with far more punch than that price action suggests. H1 2026 revenue reached ¥12,712.2m and net income came in at ¥985.3m, which translates to basic earnings per share of ¥0.47. For a stock trading on a P/E of 7.8x, the key headline is simple: profitability looks stronger on recent figures than the share price...

Innovent Biologics (SEHK:1801) caught investor attention after reporting product revenue of over CN¥4.3b for Q2 2026 and more than CN¥8.2b for the first half, supported by its dual engine growth strategy. See our latest analysis for Innovent Biologics. Those revenue headlines have arrived alongside firm share price momentum, with Innovent Biologics delivering a 30 day share price return of 8.66% and a 90 day share price return of 21.73%, while the three year total shareholder return of...

Cowell e Holdings closed at HK$24.8 after the earnings release, with the stock coming in on the back of a mixed few months that included a recent 7 day gain and a weaker 90 day stretch. The headline from this set of numbers is not revenue size but profitability quality. Net income from continuing operations over the last twelve months reached US$217.2m and basic earnings per share for that period came in at US$0.254924. The market now has to decide if today’s move fairly reflects that...

China Industrial Securities International Financial Group closed today at HK$0.63, with the stock barely budging over the past month. The calm share price masks a sharp earnings step up. First half 2026 net income reached HK$137.7 million, with basic earnings per share at HK$0.0344. The trailing twelve month net profit margin sits at 21.3%. For a capital markets firm, that level of profitability is the key development. Short term traders may focus on the flat chart, while long term investors...

Guangzhou Xiao Noodles Catering Management stock closed at HK$3.37 on Tuesday after a choppy few months, with the share price down about 20% over 90 days. The immediate reaction masks a clearer story in the new half-year numbers. Revenue reached C¥939.4m in H1 2026 and basic earnings per share came in at C¥0.0908, which keeps the trailing P/E near 16x. For long-term investors the key question now is how this profit profile and reported margin improvement relate to the current valuation. Is...

Shanghai Fudan Microelectronics Group stock closed at HK$26.92, capping a modestly positive week on the screen, while the latest quarter’s headline numbers point to something far more dramatic beneath the surface. Q2 basic earnings per share jumped to CN¥0.85 on revenue of about CN¥1.19b, a sharp reset from recent quarters for a chip maker that had just reported a loss at the end of 2025. The short term move looks relatively tame by comparison with that swing in profitability, which is what...

Guoquan Food (Shanghai) stock has been under pressure, with the share price declining over the past week and quarter even after closing at HK$1.98 today. The headline from these H1 2026 results is not a collapse in demand. It is the strain on profitability that investors need to weigh against the low valuation. Net income for the half year came in at ¥211.246m on revenue of ¥3,946.859m, while trailing 12 month earnings growth of 40.5% sits on top of a P/E of 9.4x. The short term price...

Geely Automobile Holdings just printed another quarter of solid top and bottom line numbers, yet the stock is stuck around HK$18.26 after a flat week and a weak 3 month run. The real headline is simple: revenue for Q2 reached ¥89.8b while net income came in at ¥4.9b, and the trailing P/E sits at 10.1x, well below both peers and the wider Asian auto sector. That mix of steady earnings power and a discounted valuation sets up a clear sentiment test. The market is still treating Geely like a...